Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. (Nasdaq: LFWD) is a medical device company that focuses on technologies for physical rehabilitation and recovery, including the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System. This news page aggregates company press releases and third-party coverage so readers can follow how Lifeward’s business and strategy develop over time.
Recent news highlights Lifeward’s progress in reimbursement and market access for its ReWalk 7 Personal Exoskeleton. The company has reported prior authorization approvals and payments from Medicare Advantage plans, including UnitedHealthcare and a Humana Medicare Advantage Plan, following the establishment of a formal Medicare reimbursement pathway for personal exoskeletons by CMS. These updates provide insight into payer adoption trends and Lifeward’s efforts to support access for individuals with spinal cord injury.
Lifeward’s news flow also covers international expansion and regulatory milestones. The company announced CE mark approval for the ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe, and a distribution agreement with Verita Neuro to offer ReWalk in Mexico, Thailand, and the United Arab Emirates. These items help investors and clinicians understand how Lifeward is extending its commercial footprint beyond its core markets in the United States, Israel, and Germany.
Another important theme in Lifeward’s news is its strategic partnership with Oramed Pharmaceuticals. The parties have agreed to transfer Oramed’s Protein Oral Delivery (POD™) technology to Lifeward, with Oramed becoming a significant shareholder and managing the clinical program. Coverage of this transaction explains how Lifeward aims to operate as a biomedical portfolio company that combines revenue-generating MedTech products with longer-term biotech opportunities.
Visitors can use this page to review updates on financial results, capital raises, board and management changes, regulatory approvals, reimbursement developments, and strategic transactions involving LFWD.
Lifeward (Nasdaq: LFWD) presented decade-plus real‑world safety data for the ReWalk Personal Exoskeleton at ASIA 2026. A global 2013–2025 dataset shows a 3% lifetime lower‑extremity fracture prevalence, falling to 0.3% in 2020–2025. A Germany registry (2018–2025) reports zero fractures among 97 tracked users since 2018.
The analysis links most fracture events to earlier years (87% in 2014–2019) and highlights diverse patient profiles, device iterations, and increased training and device changes as likely contributors to improved safety.
Lifeward (Nasdaq: LFWD) closed its strategic partnership with Oramed on March 25, 2026, acquiring Oramed's clinical-stage POD™ protein oral delivery technology and positioning the company as a diversified biomedical innovator with an asserted clear path to profitability.
Lifeward gained access to up to $47 million of capital from Oramed and certain investors and accessed $10 million on March 25, 2026; the company also implemented changes to its board of directors.
Lifeward (Nasdaq: LFWD) reported Q4 and full‑year 2025 results and announced a shareholder‑approved strategic transaction with Oramed that transfers the POD™ oral protein delivery platform to Lifeward and could provide up to $47 million in funding.
2025 revenue was $22.0M, net loss $19.9M, GAAP operating expenses fell 25%, and unrestricted cash was $2.2M. Lifeward also agreed to acquire an upper‑body exoskeleton and secured expanded U.S. Medicare Advantage reimbursement for ReWalk.
Lifeward (Nasdaq: LFWD) received shareholder approval to close a strategic partnership with Oramed (Nasdaq: ORMP) that integrates Oramed’s POD™ oral protein delivery platform into Lifeward while Oramed acquires a significant equity stake.
The structure provides Lifeward potential access to up to $47 million, keeps Oramed responsible for POD™ clinical funding, and aims to combine near‑term MedTech profitability with long‑term biotech upside.
Lifeward (Nasdaq: LFWD) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, a condition satisfied on March 9, 2026. The Nasdaq Listing Qualifications Staff considers the prior bid price deficiency closed and Lifeward ordinary shares will continue trading on The Nasdaq Capital Market.
Lifeward (Nasdaq: LFWD) will report fourth quarter and full year 2025 financial results before markets open on March 18, 2026. A live conference call and webcast with CEO Mark Grant and CFO Almog Adar begins at 8:30 a.m. EST. An archived webcast will be available on the Investors Events Calendar.
Lifeward (Nasdaq: LFWD) announced a collaboration with Shirley Ryan AbilityLab to launch dedicated clinic days in Q2 2026 to accelerate evaluation and access to the ReWalk Personal Exoskeleton for people with spinal cord injury (SCI).
Shirley Ryan AbilityLab will lead clinical evaluation, training and patient support, while Lifeward provides ReWalk, an FDA-cleared wearable robotic system enabling standing, walking, and navigation of stairs and curbs.
Lifeward (Nasdaq: LFWD) agreed to acquire upper-body exoskeleton technology and prototypes from Skelable for $480,000 in Lifeward equity plus a nominal cash payment, with the Skelable engineering team joining Lifeward.
The device targets post-stroke upper-limb rehabilitation; Lifeward expects commercial readiness in ~18–24 months following development and regulatory approvals.
Lifeward (Nasdaq: LFWD) will effect a 1-for-12 reverse share split effective at market open on February 24, 2026, combining every twelve issued ordinary shares into one share and assigning a new CUSIP (M8216Q309).
The Board also increased authorized share capital to 100,000,000 shares. The company expects shares outstanding to fall from ~18.3 million pre-split to ~1.5 million post-split and says the move aims to meet Nasdaq's $1.00 bid-price continued listing standard.
Lifeward (Nasdaq: LFWD) announced on Feb 17, 2026 that Aetna issued a prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, joining Humana and UnitedHealthcare.
Coverage now spans three major Medicare Advantage insurers, representing approximately 16 million beneficiaries, for qualified individuals meeting medical necessity criteria.
The ReWalk Personal Exoskeleton is FDA-approved; peer-reviewed studies cited benefits for ambulation, musculoskeletal health, and cardiopulmonary function.